沙利度胺联合CHOP方案对弥漫性大B细胞淋巴瘤患者疗效观察及对外周血Th17细胞及其相关因子的影响

李丽; 杨一飞; 杨俊超; 毛丹; 周丽云

doi:10.13201/j.issn.1004-2806.2018.11.013

沙利度胺联合CHOP方案对弥漫性大B细胞淋巴瘤患者疗效观察及对外周血Th17细胞及其相关因子的影响

- 1. 河北工程大学附属医院血液内科(河北邯郸, 056000);
- 2. 河北工程大学临床医学院学科建设与研究生教育办公室
基金项目:
河北省重点研发计划健康医疗与生物医药专项项目(No:18277782D)

邯郸市科技局研究与发展计划项目(No:1723208068-2)

详细信息

通讯作者: 杨一飞,E-mail:yyfwjw@126.com

中图分类号: R733.4

收稿日期: 2017-05-06

Effect of thalidomide combined with CHOP regimen for patients with diffuse large B cell lymphoma and its curative effect on peripheral blood Th17 cells and related factors

More Information

Corresponding author: , E-mail: yyfwjw@126.com

Received Date: 06 May 2017

摘要

- 沙利度胺 /
- CHOP方案 /
- 弥漫性大B细胞淋巴瘤 /
- 临床疗效 /
- Th7细胞
- thalidomide /
- CHOP regimen /
- diffuse large B cell lymphoma /
- clinical efficacy /
- Th17cells

HTML全文

参考文献(11)

[1]	中华医学会血液学分会、中国抗癌协会淋巴瘤专业委员会.中国弥漫大B细胞淋巴瘤诊断与治疗指南(2013年版)[J].中华血液学杂志,2013,34(9):816-819.
[2]	葛均波,徐永健.内科学[M].8版.北京:人民卫生出版社,2013:596-598.
[3]	Hunt KE,Reichard KK.Diffuse large B-cell lymphoma[J].Arch Pathol Lab Med,2008,132:118-124.
[4]	Harrington LE,Hatton RD,Mangan PR,et al.Interleukin 17-producing CD4+efector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages[J].Nat Immunol,2005,6:1123-1132.
[5]	马婷婷,马敏.Th17细胞在弥漫大B细胞淋巴瘤中的研究进展[J].临床血液学杂志,2017,30(7):564-567.
[6]	钟伟杰,李庆山,许昕,等.弥漫大B细胞淋巴瘤患者Th17细胞及相关细胞因子水平与预后的关系[J].广东医学,2016,37(5):674-677.
[7]	Yang ZZ,Novak AJ,Ziesmer SC,et al.Malignant B cells skew the balance of regulatory T cells and TH17 cells in B-cell non Hodgkin's lymphoma[J].Cancer Res,2009,69:5522-5530.
[8]	Singhal S,Mehta J,Desikan R,et al.Antitumor activity of thalidomide in refractory multiple myeloma[J].N Engl J Med,1999,341:1565-1571.
[9]	Moehler T.Clinical experience with thalidomide and lenalidomide in multiple myeloma[J].Curr Cancer Drug Targets,2012,12:372-390.
[10]	Breitkreutz I,Anderson KC.Thalidomide in multiple myelomaclinical trials and aspects of drug metabolism and toxicity[J].Expert Opin Drug Metab Toxicol,2008,4:973-985.
[11]	Pro B,Younes A,Albitar M,et al.Thalidomide for patients with recurrent lymphoma[J].Cancer,2004,100:1186-1189.